51 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, research and development plans, information relating to the customers, suppliers, business partners, clients, finances, business plans and products … Exploitation or other research or development activity directed towards any one or more Oncology Indication and/or in relation to the understanding
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
and expertise than it does in research and development, manufacturing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products … that Tenet or its licensors may not identify patentable aspects of its research and development output before it is too late to obtain patent protection
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
in the Territory to use the Cell Line in which the GlymaxX® Technology is applied for the research, development, manufacture, use, sale and offer for sale … with the terms and conditions of this Agreement. ProBioGen’s activities under this agreement are research and development activities with uncertain results
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
(Unaudited)
(in thousands)
Three Months
Ended
March 31, 2024
Operating expenses:
Research and development, related party
In-process research … :
Change in fair value of simple agreements for future equity liability
Acquired in-process research and development
Changes in operating assets
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
,
Operating expenses:
Research and development, related party
General and administrative, related party
Total operating expenses
Loss from operations
Other … additional funds, the Company may be forced to delay, scale back or eliminate some of the Company’s research and development activities, or other
8-K
EX-99.6
vnqv4a5nb 84
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
hft1lvgviudb2ta03tv
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
DEFA14A
kktp9575
14 Jun 24
Additional proxy soliciting materials
5:02pm
DEFM14A
zqgyae
4 Jun 24
Proxy related to merger
8:00am
PREM14A
0wkq5wfklmxgbg gqrj
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
ga2r8ch5cndlodz4vh
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
9j9 vwzlu20yz0
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
ti6feg955itbv
11 May 23
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
4:12pm